Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study

The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gatin...

Descripción completa

Detalles Bibliográficos
Autores: Verbeek, Martijn W. C., Buracchi, Chiara, Laqua, Anna, Nierkens, Stefan, Sedek, Lukasz, Flores-Montero, Juan, Hofmans, Mattias, Costa, Elaine S., Novákova, Michaela, Mejstrikova, Ester, Barrena, Susana, Kohlscheen, Saskia, Szczepanowski, Monika, Kulis, Jan, Oliveira, Elen, Jugooa, Romana, Jong, Anja X. de, Szczepanski, Tomasz, Philippé, J., Dongen, J. J. M. van, Orfao, Alberto, Brüggemann, Monika, Gaipa, Giuseppe, Velden, Vincent H. J. van der
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/282850
Acceso en línea:http://hdl.handle.net/10261/282850
Access Level:acceso abierto
Palabra clave:Acute leukaemia
Diagnostic haematology
Flow cytometry
Minimal residual disease
id ES_04bd737e1f5aa16cd53e43383fa155c7
oai_identifier_str oai:digital.csic.es:10261/282850
network_acronym_str ES
network_name_str España
repository_id_str
spelling Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow studyVerbeek, Martijn W. C.Buracchi, ChiaraLaqua, AnnaNierkens, StefanSedek, LukaszFlores-Montero, JuanHofmans, MattiasCosta, Elaine S.Novákova, MichaelaMejstrikova, EsterBarrena, SusanaKohlscheen, SaskiaSzczepanowski, MonikaKulis, JanOliveira, ElenJugooa, RomanaJong, Anja X. deSzczepanski, TomaszPhilippé, J.Dongen, J. J. M. vanOrfao, AlbertoBrüggemann, MonikaGaipa, GiuseppeVelden, Vincent H. J. van derAcute leukaemiaDiagnostic haematologyFlow cytometryMinimal residual diseaseThe standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.The EuroFlow Consortium received support from the FP6-2004-LIFESCIHEALTH-5 programme of the European Commission (grant LSHB-CT-2006-018708) as Specific Targeted Research Project (STREP). The EuroFlow Consortium is part of the European Scientific Foundation for Hemato-Oncology (ESLHO), a Scientific Working Group (SWG) of the European Hematology Association (EHA). TS and LS were supported by a Scientific Grant from the Medical University of Silesia Nr. PCN-1-050/K/0/K.John Wiley & SonsEuropean CommissionEuropean Hematology AssociationSilesian University of TechnologyConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2022202220222022info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/282850reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttp://dx.doi.org/10.1111/bjh.17992Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2828502026-05-22T06:33:51Z
dc.title.none.fl_str_mv Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study
title Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study
spellingShingle Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study
Verbeek, Martijn W. C.
Acute leukaemia
Diagnostic haematology
Flow cytometry
Minimal residual disease
title_short Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study
title_full Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study
title_fullStr Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study
title_full_unstemmed Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study
title_sort Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study
dc.creator.none.fl_str_mv Verbeek, Martijn W. C.
Buracchi, Chiara
Laqua, Anna
Nierkens, Stefan
Sedek, Lukasz
Flores-Montero, Juan
Hofmans, Mattias
Costa, Elaine S.
Novákova, Michaela
Mejstrikova, Ester
Barrena, Susana
Kohlscheen, Saskia
Szczepanowski, Monika
Kulis, Jan
Oliveira, Elen
Jugooa, Romana
Jong, Anja X. de
Szczepanski, Tomasz
Philippé, J.
Dongen, J. J. M. van
Orfao, Alberto
Brüggemann, Monika
Gaipa, Giuseppe
Velden, Vincent H. J. van der
author Verbeek, Martijn W. C.
author_facet Verbeek, Martijn W. C.
Buracchi, Chiara
Laqua, Anna
Nierkens, Stefan
Sedek, Lukasz
Flores-Montero, Juan
Hofmans, Mattias
Costa, Elaine S.
Novákova, Michaela
Mejstrikova, Ester
Barrena, Susana
Kohlscheen, Saskia
Szczepanowski, Monika
Kulis, Jan
Oliveira, Elen
Jugooa, Romana
Jong, Anja X. de
Szczepanski, Tomasz
Philippé, J.
Dongen, J. J. M. van
Orfao, Alberto
Brüggemann, Monika
Gaipa, Giuseppe
Velden, Vincent H. J. van der
author_role author
author2 Buracchi, Chiara
Laqua, Anna
Nierkens, Stefan
Sedek, Lukasz
Flores-Montero, Juan
Hofmans, Mattias
Costa, Elaine S.
Novákova, Michaela
Mejstrikova, Ester
Barrena, Susana
Kohlscheen, Saskia
Szczepanowski, Monika
Kulis, Jan
Oliveira, Elen
Jugooa, Romana
Jong, Anja X. de
Szczepanski, Tomasz
Philippé, J.
Dongen, J. J. M. van
Orfao, Alberto
Brüggemann, Monika
Gaipa, Giuseppe
Velden, Vincent H. J. van der
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv European Commission
European Hematology Association
Silesian University of Technology
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Acute leukaemia
Diagnostic haematology
Flow cytometry
Minimal residual disease
topic Acute leukaemia
Diagnostic haematology
Flow cytometry
Minimal residual disease
description The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/282850
url http://hdl.handle.net/10261/282850
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv http://dx.doi.org/10.1111/bjh.17992
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv John Wiley & Sons
publisher.none.fl_str_mv John Wiley & Sons
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402812289384448
score 15,811543

Similares en LA Referencia